An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
Data Collection
Varicella Zoster Virus Infection+28
+ Blood-Borne Infections
+ Urogenital Diseases
Treatment Study
Summary
This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Key Eligibility Criteria: * Must have completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114. * Demonstrated adherence to protocol requirements during Study C111, and willing and able to comply with protocol requirements for the duration of the study participation. * Must not have had any serious adverse experience since enrollment in Study C111, whether or not considered to be study drug-related. * Must have intact skin at the treatment area. * Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks). * Must not use topical pain medications on painful areas. * Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. * No history or current problem with substance abuse.